卵巢癌每年检测并没有降低死亡率
一项由NIHR资助的卵巢癌年度筛查的大规模随机试验表明，尽管某种筛查方法更早地检测出癌症，但未能成功地降低该病的死亡率。
Results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) have been published in a report in the medical journal The Lancet.
英国卵巢癌筛查协作试验(UKCTOCS)的结果发表在医学杂志《柳叶刀》上。
In the UK, 4,000 women die from ovarian cancer each year. It is not usually diagnosed until it is at a late stage and hard to treat. UKCTOCS was designed to test the hypothesis that a reliable screening method that picks up ovarian cancer earlier, when treatments are more likely to be effective, could save lives.
在英国，每年有4000名妇女死于卵巢癌。病患没有前期筛查，发现时已经是晚期，难以治疗。UKCTOCS的设计是为了验证这样一个假设，即在治疗尚且有效时更早地发现卵巢癌，从而挽救生命。
The latest analysis looked at data from more than 200,000 women aged 50-74 at recruitment who were followed up for an average of 16 years. The women were randomly allocated to one of three groups: no screening, annual screening using an ultrasound scan, and annual multimodal screening involving a blood test followed by an ultrasound scan as a second line test.
这项最新的分析调查了20多万名年龄在50-74岁之间的女性的数据，这些女性平均随访了16年。这些妇女被随机分配为三组：不筛查，每年进行筛查，每年进行多模式筛查，包括血液检测，然后进行超声扫描作为二线检测。
The researchers found that, while the approach using multimodal testing succeeded in picking up cancers at an early stage, neither screening method led to a reduction in deaths.
研究人员发现，虽然使用多模式检测的方法成功地在早期发现了癌症，但这两种筛查方法都没有降低死亡率。
Professor Usha Menon (MRC Clinical Trials Unit at UCL), lead investigator of UKTOCS, said: “UKCTOCS is the first trial to show that screening can definitely detect ovarian cancer earlier. However, this very large, rigorous trial shows clearly that screening using either of the approaches we tested did not save lives. We therefore cannot recommend ovarian cancer screening for the general population using these methods.
UKCTOCS的首席研究员Usha Menon教授(UCL的MRC临床试验部门)说：“UKCTOCS是第一个表明筛查可以更早发现卵巢癌的试验。然而，这个非常大的、严格的试验清楚地表明，使用我们测试的任何一种方法进行筛查都不能挽救生命。因此，我们不能推荐使用这些方法对普通人群进行卵巢癌筛查。”
“We are disappointed as this is not the outcome we and everyone involved in the trial had hoped and worked for over so many years. To save lives, we will require a better screening test that detects ovarian cancer earlier and in more women than the multimodal screening strategy we used.”
“我们很失望，因为这不是我们多年来所希望和努力的结果。为了挽救生命，我们需要一种更好的筛查方法，比我们使用的多模式筛查策略更早地发现卵巢癌，并应用到更多的女性中。”
Professor Nick Lemoine, Medical Director, NIHR Clinical Research Network, said: “These important findings from a large-scale trial, involving 200,000 participants, show that annual screening did not succeed in reducing deaths from ovarian cancer.
NIHR临床研究网络的医学主任Nick Lemoine教授说：“一项涉及20万参与者的大规模试验的这些重要发现表明，每年一次的筛查并没有成功地减少卵巢癌的死亡率。
“However, it’s important to note that negative results can be as important as positive. The study has provided important new evidence and insights into how to conduct and analyse future large-scale randomised clinical trials into ovarian cancer, in the hope that this will prevent and diagnose this disease more effectively in the future.
“然而，值得注意的是，负面结果可能和正面结果一样重要。这项研究为今后如何开展和分析卵巢癌的大规模随机临床试验提供了重要的新证据和见解，希望能在今后更有效地预防和诊断卵巢癌。
"We thank every single person who took part.”
“我们感谢每一位参与者。”
